The structure of the class II fructose-1,6-bisphosphatase from F. tularensis is presented together with kinetic data for the wild type and the active-site mutant Thr89Ser. The structure reveals a tetramer of four identical subunits with approximate 222 symmetry. The structure is related to the homologous structure from the related pathogen Mycobacterium tuberculosis.
Keywords: class II FBPases; fructose-1,6-bisphophatase; Mycobacterium tuberculosis; Francisella tularensis; antibiotic targets
Abstract
The crystal structure of the class II fructose-1,6-bisphosphatase (FBPaseII) from the important pathogen Francisella tularensis is presented at 2.4 Å resolution. Its structural and functional relationships to the closely related phosphatases from Mycobacterium tuberculosis (MtFBPaseII) and Escherichia coli (EcFBPaseII) and to the dual phosphatase from Synechocystis strain 6803 are discussed. FBPaseII from F. tularensis (FtFBPaseII) was crystallized in a monoclinic crystal form (space group P21, unit-cell parameters a = 76.30, b = 100.17, c = 92.02 Å, β = 90.003°) with four chains in the asymmetric unit. Chain A had two coordinated Mg2+ ions in its active center, which is distinct from previous findings, and is presumably deactivated by their presence. The structure revealed an approximate 222 (D 2) symmetry homotetramer analogous to that previously described for MtFBPaseII, which is formed by a crystallographic dyad and which differs from the exact tetramer found in EcFBPaseII at a 222 symmetry site in the crystal. Instead, the approximate homotetramer is very similar to that found in the dual phosphatase from Synechocystis, even though no allosteric effector was found in FtFBPase. The amino-acid sequence and folding of the active site of FtFBPaseII result in structural characteristics that are more similar to those of the previously published EcFBPaseII than to those of MtFBPaseII. The kinetic parameters of native FtFBPaseII were found to be in agreement with published studies. Kinetic analyses of the Thr89Ser and Thr89Ala mutations in the active site of the enzyme are consistent with the previously proposed mechanism for other class II bisphosphatases. The Thr89Ala variant enzyme was inactive but the Thr89Ser variant was partially active, with an approximately fourfold lower K m and V max than the native enzyme. The structural and functional insights derived from the structure of FtFBPaseII will provide valuable information for the design of specific inhibitors.
1. Introduction
Francisella tularensis, which causes tularemia, is one of the most virulent and deadly pathogens to be registered as a biological weapon (Dennis et al., 2001 ▸). Highly pathogenic biovars of F. tularensis have been discovered in all parts of the world. The first isolation of F. tularensis subsp. tularensis occurred in Europe (Guryčová, 1998 ▸). The pathogen is capable of infecting various types of cells from more than 250 hosts, but in humans it is thought to replicate intracellularly to high densities mainly in macrophages (Santic et al., 2006 ▸; Sjöstedt, 2006 ▸; Keim et al., 2007 ▸). Clinical outcomes in the treatment of tularemia often correlate poorly with the results from in vitro experiments on susceptibility to antibiotics.
Traditionally, antibiotic therapies for tularemia have been determined empirically by testing the bactericidal or bacteriostatic effect using whole cells, and most of the useful drugs were found to be toxic or only resulted in a bacteriostatic effect. Therefore, more effective and less toxic drugs are in demand. One approach to pursue a bactericidal effect is the rational design of drugs that target the essential metabolic pathways. It has been demonstrated that gluconeogenesis, but not glycolysis, is essential for the intracellular growth and virulence of F. tularensis (Brissac et al., 2015 ▸). Genetic screens resulted in the identification of the gluconeogenic enzyme class II fructose-1,6-bisphosphatase (FtFBPaseII), the product of the glpX gene, as one of the most important contributors to the virulence of F. tularensis strains SchuS4 and LVS (Kadzhaev et al., 2009 ▸). Further work has demonstrated that Francisella relies on the supply of amino acids from the host as major gluconeogenic substrates for intracellular growth (Ziveri et al., 2017 ▸), highlighting the importance of the FtFBPaseII enzyme; no other FBPases have been characterized in F. tularensis. Thus, targeted inactivation of FtFBPaseII should prevent the bacterium from producing fructose 6-phosphate (F6P) during intracellular growth, regardless of the specific gluconeogenic host-derived carbon source that is available to the pathogen (Radlinski et al., 2018 ▸). F6P is a precursor of the pentose phosphate pathway and is necessary for the de novo synthesis of molecules that are essential for the survival of F. tularensis in the host, including lipopolysaccharides, peptidoglycan and pentose phosphates.
FBPases are a broad group of enzymes consisting of five different classes (I–V) which share similarities in amino-acid sequence and consequently in structural fold. Prokaryotic FBPases are diverse and contain members of all five classes, while eukaryotic FBPases are mostly limited to class I, which provides the opportunity for the design of bacterial FBPase inhibitors that are harmless to mammalian enzymes. Similarity in the structure of all classes of FBPases is displayed by the presence of two adjacent α/β domains, one of which is usually two-layered (α–β ; CATH code 3.30.540), with the other being three-layered (α–β–α ; CATH code 3.40.190). Together, these domains form a five-layered sandwich-like structure (α–β–α–β–α), in which the β-sheets are positioned nearly orthogonal to each other. Class-specific structural differences include the number of strands in each sheet, the boundaries of the strands and the topology connecting them. A number of FBPase class II structures have been reported to date of both apo enzymes and complexes with different effectors. FtFBPaseII has high (∼50%) amino-acid sequence identity and is assumed to be structurally homologous to other bacterial class II FBPases, such as those from Mycobacterium tuberculosis (MtFBPaseII) and Escherichia coli (EcFBPaseII) and in particular the dual enzyme fructose-1,6-/sedoheptulose-1,7-bisphophatase from the cyanobacterium Synechocystis strain 6803. Structures of these three enzymes in the apo form and bound to various ligands are available from the Protein Data Bank: PDB entries 6ayy, 6ayu and 6ayv for MtFBPaseII (Wolf et al., 2018 ▸), PDB entries 3big, 3bih and 3d1r for EcFBPaseII (Brown et al., 2009 ▸), and PDB entries 3roj and 3rpl for the Synechocystis dual enzyme (Feng et al., 2014 ▸).
Despite the increasing number of available structures, there are still biochemical and functional questions that need to be addressed in order to successfully establish structure-guided drug-design projects targeting FtFBPaseII. Some of the ambiguities relate to the native oligomeric state of the enzyme, the enzyme stability in solution and the exact nature of the metal cofactors and their stoichiometry in the active site.
The functional quaternary structures of class II FBPases in solution are diverse, ranging from a proposed dimer for EcFBPaseII (Brown et al., 2009 ▸) to a described tetramer for MtFBPaseII (Wolf et al., 2018 ▸). These enzymes were found as tetrameric aggregates in the crystal, with monomers and dimers in the asymmetric unit, respectively. To date, only the crystal structure of the Synechocystis dual enzyme in the presence of the allosteric effector AMP has been found to contain a full tetramer in the asymmetric unit (PDB entry 3rpl; Feng et al., 2014 ▸). FtFBPaseII has been observed as a mixture of dimers and tetramers in solution, with the larger tetrameric state being found at higher protein concentrations (Gutka et al., 2017 ▸). The structure-based design of compounds aimed at disruption of the native oligomeric state of FtFBPaseII could be a promising strategy for successful rational drug design in order to bypass the high polarity of compounds binding in the active site.
A preference for Mn2+ as a metal cofactor together with weak Li+ sensitivity makes FtFBPaseII similar to EcFBPaseII (Gutka et al., 2017 ▸; Brown et al., 2009 ▸). However, the majority of known FBPases can be activated by Mg2+ or by a mixture of Mg2+ and Mn2+, and are readily deactivated by Li+. Surprisingly, the presence of Mg2+ in the active site of FtFBPaseII completely inhibits activity (Gutka et al., 2017 ▸). The structural basis for these specificities is unknown and could also be exploited for the purpose of designing compounds that are highly specific for FtFBPaseII. Here, we present the first crystal structure of FtFBPaseII and its comparison with other relevant members of the class II bisphosphatases in order to provide insights into the metal dependence, protein oligomeric state and enzymatic activity of FtFBPaseII.
2. Materials and methods
2.1. FtFBPaseII protein: mutagenesis, overexpression in E. coli, purification and storage
A previously engineered construct of the F. tularensis glpX gene containing an N-terminal His6 tag in pET-15b vector was used for overexpression of the FtFBPaseII enzyme in E. coli (Gutka et al., 2017 ▸). The T89S and T89A mutants in the FtFBPaseII active site were obtained using the QuikChange II site-directed mutagenesis kit (Agilent Technologies) following the manufacturer’s recommended procedure. Forward primers and their reverse complements were designed to replace the threonine at position 89 of FtFBPaseII with alanine (T89A; 5′-CCCGCTGGAAGGTGCGACCATTACCAGC-3′) and serine (T89S; 5′-CCCGCTGGAAGGTTCGACCATTACCAGC-3′). In the mutant genes, the ACG codon for Thr89 was replaced by GCG for alanine and TCG for serine. Substitutions were verified by DNA sequencing. Overexpression of the wild-type and mutant FtFBPaseIIs and the purification of the proteins from E. coli was performed as described previously (Gutka et al., 2017 ▸). All purification procedures were performed at 277 K. The enzyme was stored as single-use aliquots at 193 K until further use. Details are summarized in Supplementary Table S1.
2.2. Enzymatic assays
The protein for enzymatic assays was purified, concentrated to at least 10 mg ml−1 and stored in 20 mM Tris–HCl pH 8.0, 50 mM KCl, 7% glycerol. A previously established enzymatic assay based on two coupled reactions using phosphoglucoisomerase and glucose-6-phosphate dehydrogenase in the presence of NADP+ was used to determine the activity of FtFBPaseII (Rittmann et al., 2003 ▸; Gutka et al., 2011 ▸). The ernzymes for the assay were purchased from Sigma–Aldrich. The reactions were carried out in buffer consisting of 50 mM KCl, 50 mM MnCl2, 20 mM Tris–HCl pH 8.0 and the substrate fructose 1,6-bisphosphate (F16BP) at various concentrations. MnCl2 was added to the reaction directly before the substrate. The assay was performed in triplicate and the activities of wild-type and mutant FtFBPaseII were tested at a final concentration of 50 nM. A reaction lacking FtFBPaseII served as a negative control. The activity of FtFBPaseII in the assay was monitored by the formation of NADPH at 340 nm. Data were fitted to a Michaelis–Menten kinetic model using Prism to calculate K m and its error. The ratio V WT/V T89S for the median values of the reaction speed obtained from kinetic analysis was plotted against the corresponding substrate concentrations and fitted using Prism in order to analyze the changes in K m introduced by the mutation (Eisenthal et al., 2007 ▸).
2.3. Crystallization
The purified protein (10 mg ml−1) in 20 mM Tricine pH 7.8, 50 mM KCl, 1 mM MgCl2, 0.1 mM DTT, 15% glycerol was combined with F6P at 1 mM (a 1:4 protein:ligand ratio). The complex and apo samples were incubated overnight with the ligand at 4°C. An initial crystal (crystal A) suitable for data collection was grown in ammonium sulfate, 0.1 M bis-Tris pH 5.5, 17% PEG 10 000 at a protein concentration of 10 mg ml−1 in the presence of the substrate F16BP at 1 mM concentration. Subsequent crystallization trials were carried out at 291 K using the sitting-drop vapor-diffusion method. Drops were prepared by combining the enzyme solution with precipitant in a 1:1 volume ratio and were then equilibrated against 0.1 ml reservoir solution. The PEGs, PACT, pHClear, Classics and JCSG+ Suites (Qiagen) crystallization screens were used as the initial screening conditions. A second crystal (crystal B), which diffracted to higher resolution, was obtained using 0.2 M sodium formate, 20% PEG 3350 in the presence of F6P. Data are summarized in Supplementary Table S2.
2.4. Data collection and processing
Crystals were harvested from the drops, soaked for 15–30 s in a cryoprotectant solution consisting of reservoir solution plus 20% glycerol, mounted on nylon loops and flash-cooled by immersion in liquid nitrogen. X-ray diffraction data were collected near liquid-nitrogen temperature on the 21-ID-G beamline at the Advanced Photon Source, Argonne National Laboratory, Illinois, USA. Diffraction data sets were collected from several crystals at a wavelength of 0.97856 Å using a MAR300 detector at the Life Sciences Collaborative Access Team (LS-CAT) or Southeastern Regional Collaborative Access Team (SER-CAT) at the Advanced Photon Source (λ = 1.0000 Å).
For crystal A, 240 frames were collected (1° scan width and 1 s exposure per frame) at a crystal-to-detector distance of 280 mm, but owing to crystal decay only 200 frames were processed to a nominal resolution of 2.7 Å. A similar data-collection strategy was used for crystal B: a 180° wedge including a total of 360 frames was collected with a 0.5° scan width and an exposure time of 4 s per frame at the same crystal-to-detector distance. The data were indexed and scaled with the HKL-2000 package (Otwinowski & Minor, 1997 ▸).
2.5. Structure solution, refinement and subsequent analysis
Initial data processing, integration and data reduction at the beamline suggested that both crystals were orthorhombic (P222), with approximate unit-cell parameters a = 76, b = 101, c = 92 Å, or possibly monoclinic (P2), with a β angle of nearly 90° (range 89.56–90.06°) and with the unique twofold screw along the longest axis. The resolution limits of the data sets were in the range 2.4–2.7 Å. Further data-reduction analysis suggested that the data sets were all P21, with various degrees of twinning that resulted in pseudo-orthorhombic symmetry that dominated the self-rotation function (SRF; Fig. 1 ▸). The degree of twinning was also assessed by examining the SRF (χ = 180° projection), which provided evidence for an approximately 222 symmetry tetramer in the asymmetric unit with one of the orthogonal twofold axes inclined a few degrees (7–10°) with respect to the crystallographic c axis (Fig. 1 ▸). A data set from crystal B extending to 2.4 Å resolution with refined unit-cell parameters a = 76.30, b = 100.17, c = 92.02 Å, β = 90.003° (P21) was used for final refinement in combination with twinning corrections and estimated structure factors.
The size of the unit cell suggested that the asymmetric unit of the crystal contained four chains of FtFBPaseII (328 amino acids plus the N-terminal His tag). In addition, the SRF provided evidence for three approximately orthogonal dyads related by the crystallographic 21 screw axis. Given the high sequence identity to MtFBPaseII (∼50%), a full tetramer was assembled from the dimer in the asymmetric unit of apo MtFBPaseII (PDB entry 6ayu; Wolf et al., 2018 ▸) and used as a model for molecular-replacement searches.
The earlier 2.7 Å resolution data set (with an unknown high twinning ratio) was used in the first attempts to solve the structure by molecular replacement. A suggestive solution was found, but subsequent refinement stalled at R work = 0.30 and R free = 0.42. Given the limited quality of the data and the electron-density maps, only part (60–70%) of the amino-acid sequence of the FtFBPaseII protein could be fitted with confidence using these data. This model was subsequently used to solve and refine the structure with the best data set to 2.4 Å resolution (crystal B) using data with I/σ(I) > 3 (Table 1 ▸) to this resolution limit. Despite the significant twinning, this crystal allowed successful refinement after extensive model revisions for the different chains using the twinning option (refining against amplitudes) in REFMAC5 (Murshudov et al., 2011 ▸). The presence of a twinning law and an estimation of the twin fraction (∼0.40) was also obtained using the phenix.xtriage module of Phenix (Liebschner et al., 2019 ▸). The final refined twinning fractions were 0.574 and 0.426 for two twin domains, with twinning laws (h, k, l) and (−h, −k, l) or symmetry equivalents, respectively. Statistics for the data reduction for this data set are presented in Table 1 ▸, as well as the final refinement statistics.
Table 1. Data-collection and refinement statistics for FtFBPaseII (PDB entry 7js3).
Wavelength (Å) | 0.97856 |
Resolution (Å) | 40.0–2.40 (2.44–2.40) |
Space group | P21 |
a, b, c (Å) | 76.30, 100.17, 92.02 |
α, β, γ (°) | 90, 90.003, 90 |
Total reflections | 196190 |
Unique reflections | 53682 (2620) |
Multiplicity | 3.6 (3.7) |
Completeness (%) | 98.9 (97.5) |
Mean I/σ(I) | 24.6 (3.2) |
Wilson B factor (Å2) | 42.9 |
R meas | 0.106 (0.531) |
CC1/2 | 0.991 (0.673) |
R p.i.m. | 0.055 (0.276) |
Twinning fraction | 0.432 |
Twinning operator | h, −k, −l |
Reflections used in refinement | 53626 (2502) |
Reflections used for R free | 2732 (119) |
R work | 0.154 (0.185) |
R free | 0.193 (0.292) |
No. of non-H atoms | |
Total | 9734 |
Macromolecules | 9434 |
Ligands | 4 |
Solvent | 269 |
No. of protein residues | 1268 |
R.m.s.d. from ideal | |
Bond lengths (Å) | 0.010 |
Angles (°) | 1.24 |
Ramachandran plot | |
Favored (%) | 92.0 |
Allowed (%) | 7.6 |
Outliers (%) | 0.6 |
Clashscore | 15 |
Average B factor (Å2) | |
Overall | 52.6 |
Macromolecule | 52.7 |
Ligands | 71.9 |
Solvent | 44.9 |
The CCP4 suite of programs (Winn et al., 2011 ▸), including REFMAC5 and Coot (Emsley et al., 2010 ▸), was used for data analysis and refinement. In addition, 2–3 cycles of refinement using Phenix were typically also interspersed with the routine REFMAC5 refinement (ten cycles) to adjust the different scales and to consistently refine the twinning fraction. The extensive use of the Phenix refinement protocols resulted in the zeroing out of certain areas of the electron density in the most exterior loops that made it difficult to interpret them correctly. REFMAC5 protocols with no bulk-solvent correction were most effective in revealing the correct density for the external loops, most notably the insertion loop between Asn286 and Ser292, particularly in chain A. The interpretation of this loop in chain A was later built on the other three chains, where there was acceptable density. The same strategy was used to interpret the final 11 residues (Phe318–Ser328) of the chain, for which the density was only convincing in the final stages of the refinement (Supplementary Fig. S1). Previously, it had been interpreted as an additive in the crystallization medium.
LSQKAB (Kabsch, 1976 ▸) was used for structure analysis and superpositions, either using main-chain atoms or only Cα atoms. The superposition rotation matrices for the different pairs of subunits were used and the corresponding traces were used to extract the corresponding rotation angles. The resources of the PDBsum website were used to analyze the structure and compare the different quaternary structures (Laskowski, 2001 ▸; Laskowski et al., 2018 ▸). QtMG (McNicholas et al., 2011 ▸) was used to produce publication-quality figures.
3. Results
3.1. Protein purification
The purified protein was consistent in quality with that obtained previously for FtFBPaseII (Gutka et al., 2017 ▸). The quaternary structure of FtFBPaseII is dependent on the protein concentration (Gutka et al., 2017 ▸), with the tetrameric aggregate predominating in highly concentrated samples. The solubility of the purified wild-type and mutant proteins was high enough to allow the concentration of the samples to at least 10 mg ml−1. In order to increase the stability of the tetramer prior to experiments, all of the samples were handled and stored at concentrations of at least 10 mg ml−1, which was found to be critical for the reproducibility of the activity experiments.
3.2. Crystallization
After the characterization of crystal A, a significant screening of crystallization conditions resulted in similar prismatic crystal forms (10–100 µm) but with etched surfaces. Crystals with the least amount of twinning and with diffraction data extending to the highest resolution were grown in 0.2 M sodium formate, 20% PEG 3350 in the presence of F6P (Supplementary Table S2). However, there were significant variations in the quality and extent of the different data sets from different crystals. Crystallographic analysis showed that they all belonged to the same monoclinic (P21) space group with various degrees of twinning. In subsequent analysis, a data set from a crystal with the least amount of twinning was selected for the final refinement.
3.3. Quaternary structure
The crystal structure of FtFBPaseII revealed that an entire tetramer assembly (chains A–D) with approximate 222 (D 2) symmetry was present in the asymmetric unit in the absence of any allosteric cofactors, giving support to the notion that this is the native oligomeric state under the crystallization conditions. Analysis of the corresponding inter-chain symmetry operations (Supplementary Table S3a) of the tetramer showed that the rotation angles ranged from 178.6° to 179.8° with negligible translational components.
This aggregation state has also been found in the asymmetric unit of the crystals of the Synechocystis dual enzyme (PDB entry 3rpl), in which the orthogonal symmetry operations were closer to exact twofold (179.7–179.9°) symmetry. This oligomeric arrangement is also consistent with the proposed tetramer in the structure of MtFBPaseII created by the crystallographic twofold, duplicating the dimer (AB) in the asymmetric unit (Wolf et al., 2018 ▸). The rotations that relate chains A and B in the asymmetric unit of native and T84S variant MtFBPaseII are nearly the same, averaging 176.4° (Supplementary Table S3b). These values suggest minor differences among the orientation of the different subunits in the corresponding tetramers. Although there was only one monomer in the asymmetric unit for the first reported structure of the E. coli enzyme, a dimer was suggested in the initial report, and an exact 222 symmetry tetramer was subsequently suggested by the presence of a 222 symmetry center in the crystal lattice (Brown et al., 2009 ▸; Wolf et al., 2018 ▸).
A quantitative comparison of the tetramer interfaces in the structure of FtFBPaseII with those in the structure with PDB code 3rpl, which also contains a full tetramer in the asymmetric unit of the hexagonal lattice (P65; Table 2 ▸), reveals a consistent pattern of interactions. The equivalent interfaces (A–D and B–C) in the two oligomers are formed by the largest number of hydrogen bonds, although the FtFBPaseII tetramer contains more polar interactions. This is the dimer interface (A–D) that was initially highlighted in the structure of EcFBPaseII, where the contact surface is dominated by two long antiparallel β-strands forming an extended β-sheet (Fig. 2 ▸ a) perpendicular to the dyad. The other two equivalent interfaces (A–B and C–D) were revealed as important in the asymmetric unit of MtFBPaseII (Wolf et al., 2018 ▸), with a rather large number of nonbonded contacts in PDB entry 3rpl (184–195) and approximately the same contacts in FtFBPaseII (187–189), with an additional three salt bridges (Table 2 ▸).
Table 2. Tetramer interfaces.
Chains | No. of residues | Interface area† (Å2) | No. of salt bridges | No. of hydrogen bonds | No. of nonbonded contacts |
---|---|---|---|---|---|
PDB entry 3rpl | |||||
A–B | 27:26 | 1320:1300 | — | 16 | 184 |
C–D | 26:27 | 1365:1340 | — | 19 | 195 |
A–D | 28:26 | 1580:1580 | 3 | 20 | 147 |
B–C | 30:27 | 1610:1600 | 3 | 20 | 154 |
A–C | 1:1 | 36:36 | — | — | 1 |
B–D | 1:1 | 34:36 | — | — | 1 |
FtFBPase | |||||
A–B | 30:30 | 1480:1500 | 3 | 21 | 187 |
C–D | 31:29 | 1460:1460 | 3 | 16 | 189 |
A–D | 24:33 | 1480:1410 | 5 | 23 | 157 |
B–C | 25:33 | 1330:1380 | 5 | 19 | 149 |
A–C ‡ | 2:2 | 110:110 | — | 1 | 4 |
B–D ‡ | 1:1 | 80:80 | — | — | 2 |
Interface area figures have been rounded to their last significant values.
Interfaces A–C and B–D are not considered equivalent according to the PDBsum protein–protein interaction analysis software.
3.4. Three-dimensional structure
Given the different crystallographic environments of the four chains in the asymmetric unit, the quality of the tertiary structures of the different chains (A–D) varies significantly. In the proximity of the active-site region, the presence or absence of Mg2+ cations makes an appreciable difference in ordering the amino-acid side chains in their proximity. Chains A and B are the best defined in terms of electron density and structural quality, followed by D and C, respectively. The numbers of Ramachandran outliers are 0, 2, 3 and 3, respectively.
Chain A of FtFBPaseII definitively establishes the details of the secondary structure and the tertiary fold of the FtFBPaseII enzyme as a five-layer α/β sandwich very similar to the structures of EcFBPaseII (PDB entry 3d1r) and MtFBPaseII (PDB entries 6ayy, 6ayu and 6ayv) and the Synechocystis dual enzyme (PDB entry 3rpl), although distinct features are also present. The secondary-structure analysis reveals the presence of 14 α-helices and 14 β-strands of different lengths organized into two nearly orthogonal β-sheets (sheets A snd B; Supplementary Fig. S2). A significant component of β-sheet A is a distinct ψ-loop comprising residues Asp48–Asp84 that forms the first three most external β-strands; a similar feature is also present in β-sheet B but is not as prominent or well defined. These external strands of sheet A have the highest temperature factors of all of the residues in chains A and B and are not as well defined in chains C and D. The insertions and deletions suggested by the amino-acid sequence alignment are typically accommodated outside the secondary-structural elements by ordered loops and connecting fragments (Fig. 3 ▸).
There are a few noteworthy single amino-acid differences between species (Fig. 3 ▸). Firstly, one residue is deleted in FtFBPaseII (corresponding to Asp70 in MtFBPaseII and Arg76 in EcFBPaseII) in the structurally conserved ψ-loop that ends by projecting the first metal-binding residue Asp84. Secondly, there is an insertion in MtFBPaseII of Phe113 prior to the catalytically important Tyr114 (Tyr119 in FtFBPase), which results in a local distortion prior to the catalytically conserved residue Tyr119. The insertion results in the extension in FtFBPaseII and EcFBPaseII of an aspartic acid residue (Asp116) into the metal cation site (see below; Fig. 3 ▸). Thirdly, a two-residue insertion is present in FtFBPaseII after Gly128 (Ile129-Asn130), which extends and bulges out towards the five-residue insertion (Ser287-Thr288-Arg289-Arg290-Gly291) between Asn286 and Ser292, and critically interacts with these residues in chain D of the tetramer (Fig. 3 ▸). The r.m.s.d.s between the Cα atoms of chains A and B and chains C and D of the tetramer are shown in Fig. 4 ▸(a). Finally, the C-terminal 11 amino acids adopt a unique fold forming a compact hydrophobic core that includes three Phe residues (Phe317, Phe319 and Phe326) and a short helical segment (H14), packing against Trp21 (Supplementary Fig. S1), that is unique to FtFBPase. BLAST amino-acid sequence searches of the final 11-residue sequence revealed that the sequence is highly conserved (>90%) in all species of the Francisella genus. The function of this conserved structural feature is unknown.
3.5. Comparison with other related class II FBPases
The most significant differences among the three closely related structures (EcFBPaseII, MtFBPaseII and FtFBPaseII) are in the loops extending towards the protruding helix (H12) and the return loops connecting back towards the core of the tetramer structure. These connecting loops are longer in EcFBPaseII and far shorter in the other two structures. Nonetheless, a 13-residue helical stretch (Asp237–Gly249) in FtFBPaseII superimposes in register with Gly248–Gly260 in EcFBPaseII. This helical stretch is significantly displaced in MtFBPaseII because of the presence of a two-residue insertion prior to Tyr119 in MtFBPaseII that bulges out of the otherwise regular β-strand in FtFBPaseII (Figs. 3 ▸, 4 ▸ a and 4 ▸ b). The functional significance of these helical protrusions is as yet unknown. The r.m.s.d.s between chain A of FtFBPaseII and the corresponding chain A of its closest amino-acid sequence homolog (MtFBPaseII) are shown in Fig. 4 ▸(b). The regions showing significant differences are annotated in Fig. 4 ▸(a) within the context of the overall α/β fold.
There are also noteworthy three-dimensional structure alterations in FtFBPaseII induced by the concomitant insertions after Gly126 (Ile127-Asn128) and after Asn286 (Ser287-Thr288-Arg289-Arg290-Gly291) (Figs. 3 ▸, 4 ▸ a and 4 ▸ b). Intriguingly, the two dominant polar residues of the insertion, Arg289-Arg290, are not exposed to the surface and interact rather significantly with the cluster of side chains and C=O groups of Thr198, Ser201, Ile203 and Asp204 (chain A–chain D interface). Alternatively, Arg290 interacts with the C=O group of Leu225 in chain D and the side chain of Glu314 in chain A. In addition to reinforcing the inter-chain interactions on the periphery of the tetramer by the noncrystallographic symmetry, the resulting two longer β-strands (Met278–Thr288 and Arg290–Ser303) and the connecting hairpin loop curve in a concave fashion to create a medium-sized pocket inside the tetramer that corresponds to the pocket where the allosteric effector AMP is found in the Synechocystis dual enzyme (PDB entry 3rpl). Intriguingly, this confirmed allosteric pocket is instead formed by an extension of the C-terminus, which is about 20 amino acids longer in PDB entry 3rpl.
Finally, the last 12 residues at the carboxy end of the FtFBPaseII tetramer fold form a compact hydrophobic core dominated by the presence of three Phe residues (Phe317, Phe319 and Phe326) packing next to Trp21. This conformation differs from that observed in MtFBPaseII and is significantly different in the Synechocystis dual enzyme, where it is found bound to the allosteric effector AMP in a well defined pocket (Feng et al., 2014 ▸).
3.6. Enzymatic analysis of FtFBPaseII activity
The experimentally determined reaction velocity plotted against concentration of substrate for both wild-type and T89S variant FtFBPaseII exhibited a typical Michaelis–Menten response (Fig. 5 ▸ a, Table 3 ▸). The K m of wild-type FtFBPaseII was calculated to be 17 ± 4 µM, which is in agreement with previously published observations for coupled assays with real-time measurements (Gutka et al., 2017 ▸; Supplementary Table S4 and Fig. S3). The K m for the T89S variant was determined to be 4 ± 2.1 µM, which is approximately four times lower than that of the wild-type enzyme.
Table 3. Kinetic parameters for wild-type and T89S mutant FtFBPaseII.
FtFBPaseII | K m (µM) | V max (µmol min−1 mg−1) | k cat (s−1) | k cat/K m (s−1 mM −1) |
---|---|---|---|---|
Wild type | 17 ± 4 | 0.9 ± 0.02 | 0.55 ± 0.04 | 33 |
T89S | 4 ± 2.1 | 0.2 ± 0.03 | 0.12 ± 0.02 | 31 |
Thus, wild-type FtFBPaseII needs to reach a substrate concentration of 17 ± 4 µM to reach half of its maximal velocity (0.9 µmol min−1 mg−1); this value is nearly five times higher than that for MtFBPaseII. In contrast, the T89S mutant requires about a fourfold lower substrate concentration to achieve half of its maximal velocity, which is also approximately four times lower (0.2 µmol min−1 mg−1). The turnover rate of the T89S mutant is also approximately four times lower than that of the wild type. While the wild-type enzyme takes approximately 2 s to convert one substrate molecule into product, the T89S mutant takes approximately four times longer (8 s). The k cat/K m values are approximately the same (33 and 31 s−1 mM −1, respectively) for the wild type and the T89S variant.
In view of the ambiguities and inconsistencies in using k cat/K m to compare the activities of different enzymes (mutants) for the same substrate (Eisenthal et al., 2007 ▸), we instead used the ratio of the rate of the two enzymes (V WT/V T89S) as a function of substrate concentration. The results are shown in Fig. 5 ▸(b). The analysis indicates that the ratio of the rates of the two enzymes increases linearly from 1.5 when the concentration of substrate is below or near the K m values of the enzymes, reaching a constant value of nearly 3.5 when the enzymes reach their maximum velocities (Fig. 5 ▸ b).
3.7. Active-site environment
The best-defined side-chain residues within the active-site structure are observed in chain A, where two Mg2+ sites contribute to stabilizing acidic residues. However, in the crystal structure this active-site region, in chain A only, is essentially covered by residues from the symmetrically related chain D. This packing effect results in an active site with no space left for the substrate/product (F16BP/F6P) that was present in the crystallization medium. Moreover, two residues from the symmetry-related chain D (Glu238 and Glu239) make distinct interactions with residues in the active site which, although providing a more rigid environment, are likely to affect the resulting structure by their presence.
Glu238 is positioned approximately between Mg2+(1) and Mg2+(2). The first cation is nearly octahedrally coordinated by the side chain of Asp84 and the the C=O group of Leu86 plus four water molecules. The second cation, Mg2+(2), interacts weakly in an approximately trigonal bipyramid coordination with the side chains of Glu214 and Asp116 and two water molecules at the apices of the pyramid. Asp116 extends from the main chain as a result of the sequence differences between FtFBPaseII and MtFBPaseII prior to the conserved Tyr118 (Asp116-Val117-Tyr118; Fig. 3 ▸). Superposition of the active sites of EcFBPaseII, MtFBPaseII and FtFBPaseII (chain A) (Fig. 6 ▸) reveals that the second Mg2+ site is unique to this structure and is distant (∼7.4 Å) from the cleavable phosphate group of the substrate. Thus, such a site would probably not participate in the catalytic reaction but could result in enzyme inhibition owing to its interaction with Glu214 that is normally liganded to the conserved Mg2+/Ca2+ site in the structures of MtFBPaseII (PDB entry 6ayu) and EcFBPaseII (PDB entry 3d1r) (Fig. 6 ▸).
An additional packing interaction between chain A (Arg165-Pro166-Arg167) and Asp237 from the crystallographically related chain D places its carboxylate side chain in a position and orientation similar (∼1 Å) to two phosphate O atoms of the product F6P, as observed in the MtFBPaseII–F6P (PDB entry 6ayu) complex. The two arginine residues adopt a similar conformation, as their guanidium groups are found to be positioned within 1.5 Å (1.2 and 1.5 Å) of the corresponding groups in MtFBPaseII (Arg159-Pro160-Arg161). Most likely owing to the alteration in the active site of the Mg2+-inhibited enzyme, the substrate-binding site was unoccupied, and these interactions formed instead of the normal binding of F16BP/F6P, even though the former was present in the crystallization medium at a 1 mM concentration.
4. Discussion
Protein purification using size-exclusion chromatography suggested the presence of both dimers and tetramers in solution, which was confirmed by the presence of a tetramer in the asymmetric unit of the FtFBPaseII crystals. Distinct amino-acid insertions and deletions in the polypeptide chain of FtFBPaseII seem to strengthen the interactions among the four chains of the A–D oligomer, resulting in a stable, approximately 222 symmetry tetramer for the enzymatic assembly of FtFBPase. At the concentrations used to grow the crystals, the tetramer is most likely to be the predominant species. The tetramer interfaces are conserved in the different enzymes characterized thus far, although the relative numbers of hydrogen bonds, salt bridges and nonbonded contacts vary among the residues involved. The two structures with a full tetramer in the asymmetric unit, the Synechocystis dual enzyme (PDB entry 3rpl) and FtFBPaseII, have similar numbers of residues participating in the interfaces, residues 26–30 and 22–36, respectively, although the latter has nearly double the number of salt bridges. The structure reported in this work is consistent with the previous suggestion that the native conformation of this class of enzymes is tetrameric. Whether this association implies the existence of allosteric regulators, as is the case for PDB entry 3rpl, remains unconfirmed. Confirming the existence of allosteric effectors and their binding pockets would be very important for further inhibitor design against this important class of enzymes.
The persistent presence of various degrees of twinning and our failure to grow genuine single crystals of this enzyme could be related to the approximate 222 symmetry of the tetramer, whereby tetramers with slightly different orientations along the crystal cell axes could result in twinning domains and/or disorder throughout a low-symmetry crystal lattice such as P21.
The existence of strategic insertions and deletions along the amino-acid sequence of FtFBPaseII, combined with the observed local three-dimensional structural alterations along the polypeptide chain near Tyr119, may provide a rationale for the different cation dependence, with Mg2+, Mn2+, Zn2+ and Li+ sensitivity being observed for the various members of this class. Unfortunately, our crystals grew under crystallization conditions that did not contain Mn2+, the putative genuine metal cofactor of FtFBPaseII and EcFBPaseII. Instead, Mg2+ was found in the corresponding active site. In chain A, our best-defined monomer structure, two Mg2+ sites were found. Mg2+(1) was near a Ca2+ site in EcFBPaseII with the corresponding conserved ligands. The presence of a second site Mg2+(2) next to it and interacting with Asp116, a unique ligand extending from the altered structure of the chain next to Tyr118, was observed. Asp116 in FtFBPaseII is also conserved in EcFBPaseII (Asp117) and superimposes within 1.3 Å (Cα–Cα distance) with the same side-chain orientation. Previous biochemical and enzymatic characterization of FtFBPaseII (Gutka et al., 2017 ▸) has shown that the enzyme is only active in the presence of Mn2+, as opposed to other divalent (Zn2+, Cu2+ and Ni2+) or monovalent (K+ and Na+) cations. In addition, FBPase class II enzymes that depend exclusively on Mn2+ for activity have also been found to be inhibited by Mg2+ (Gutka et al., 2017 ▸). Thus, it is reasonable to hypothesize that the crystal structure of FtFBPaseII presented here, and in particular the presence of the second Mg2+ site (above), corresponds to the Mg2+-inhibited structure, most likely owing to the presence of Mg2+ in nonproductive metal complexes instead of the catalytic Mn2+.
Initial enzymatic and kinetic studies of two FtFBPaseII protein variants at the active-site residue Thr89 (T89S and T89A) showed that the former is partially active while the latter is inactive. This observation is consistent with similar results for the MtFBPaseII enzyme (Bondoc et al., 2017 ▸). The observed reduction in the activity of the T89S mutant corresponds to an approximate fourfold reduction in the V max value and a similar reduction in the turnover number (k cat). The previously published structures of wild-type and T84S variant (with an equivalent Thr residue) MtFBPaseII complexed with the product F6P (PDB entries 6ayu and 6ayv, respectively; Wolf et al., 2018 ▸) do not show any significant differences within an 8 Å radius of the bound substrate. Thus, it is likely that the binding pockets for the substrate are unaltered between the two enzyme forms. Consequently, assuming that the hypothetical dissociation constant K d (where K d = k −1/k 1) for the substrate is essentially unchanged by the replacement of Thr89 by Ser89 in the variant enzyme, we hypothesize that the amino-acid replacement results in an enzyme that is approximately four times slower in turning over substrate into product. The detailed structural explanations of this observation are unknown, mainly because the structure of FtFBPaseII discussed does not represent an active enzyme with the native conformation of the Mn2+ metal cofactor and with substrate (or product) present.
In summary, the crystallographic structure of FtFBPaseII is presented. The structure reveals an approximately 222 symmetry tetramer in the asymmetric unit that exhibits subtle structural alterations in some peripheral loops, resulting from amino-acid residue insertions, that probably stabilize the tetrameric structure. In addition, the last 11 residues of the polypeptide adopt a compact globular structure that also contributes to the stability of the aggregate. In contrast, in other class II FBPases the tetramer is generated partially or fully by the presence of crystallographic symmetry (in MtFBPaseII and EcFBPaseII, respectively). It is uncertain whether the approximately tetrameric structure is owing to the lack of a still unknown allosteric effector. Other significant alterations were observed prior to the catalytically important Tyr118 that resulted in the projection of Asp116 into a metal ligand pocket where an Mg2+ cation was found. This cation site does not correspond to any of the sites present in other class II FBPases for which the structures are known. The suggestion is made that the present structure corresponds to an Mg2+-inhibited FBPase. Future experiments are being planned to confirm the functional importance of this structural alteration near the binding pocket of the substrate and its importance for cation specificity in class II FBPases. In addition, further enzymatic and kinetic studies will be pursued in the search for possible allosteric effectors of this class of enzymes.
Supplementary Material
Supplementary Figures and Tables. DOI: 10.1107/S2053230X20013370/dw5213sup1.pdf
Acknowledgments
The Advanced Photon Source was supported by the US Department of Energy (DE-AC02-06CH11357). We acknowledge the help of the LS-CAT staff at the Advanced Photon Source, Argonne National Laboratory with data collection on the LS-CAT 21-ID beamlines. The authors would also like to thank Professor Scott Franzblau for the support of this project from the Institute of Tuberculosis Research and Dr Shahila Mehboob for her comments on earlier versions of the manuscript. We thank Kiira Ratia of the UIC RRC for setting up the HTS co-crystallization screens.
Funding Statement
This work was funded by Potts Memorial Foundation grant G3541 to Farahnaz Movahedzadeh and Celerino Abad-Zapatero. Chicago Biomedical Consortium grant 084679-00001 to Farahnaz Movahedzadeh and Celerino Abad-Zapatero.
References
- Bondoc, J. M. G., Wolf, N. M., Ndichuck, M., Abad-Zapatero, C. & Movahedzadeh, F. (2017). Biotechnol. Rep. 15, 48–54. [DOI] [PMC free article] [PubMed]
- Brissac, T., Ziveri, J., Ramond, E., Tros, F., Kock, S., Dupuis, M., Brillet, M., Barel, M., Peyriga, L., Cahoreau, E. & Charbit, A. (2015). Mol. Microbiol. 98, 518–534. [DOI] [PubMed]
- Brown, G., Singer, A., Lunin, V. V., Proudfoot, M., Skarina, T., Flick, R., Kochinyan, S., Sanishvili, R., Joachimiak, A., Edwards, A. M., Savchenko, A. & Yakunin, A. F. (2009). J. Biol. Chem. 284, 3784–3792. [DOI] [PMC free article] [PubMed]
- Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Layton, M., Lillibridge, S. R., McDade, J. E., Osterholm, M. T., O’Toole, T., Parker, G., Perl, T. M., Russell, P. K. & Tonat, K. (2001). JAMA, 285, 2763–2773. [DOI] [PubMed]
- Eisenthal, R., Danson, M. J. & Hough, D. W. (2007). Trends Biotechnol. 25, 247–249. [DOI] [PubMed]
- Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. [DOI] [PMC free article] [PubMed]
- Feng, L., Sun, Y., Deng, H., Li, D., Wan, J., Wang, X., Wang, W., Liao, X., Ren, Y. & Hu, X. (2014). FEBS J. 281, 916–926. [DOI] [PubMed]
- Guryčová, D. (1998). Eur. J. Epidemiol. 14, 797–802. [DOI] [PubMed]
- Gutka, H. J., Rukseree, K., Wheeler, P. R., Franzblau, S. G. & Movahedzadeh, F. (2011). Appl. Biochem. Biotechnol. 164, 1376–1389. [DOI] [PubMed]
- Gutka, H. J., Wolf, N. M., Bondoc, J. M. G. & Movahedzadeh, F. (2017). Appl. Biochem. Biotechnol. 183, 1439–1454. [DOI] [PMC free article] [PubMed]
- Kabsch, W. (1976). Acta Cryst. A32, 922–923.
- Kadzhaev, K., Zingmark, C., Golovliov, I., Bolanowski, M., Shen, H., Conlan, W. & Sjöstedt, A. (2009). PLoS One, 4, e5463. [DOI] [PMC free article] [PubMed]
- Keim, P., Johansson, A. & Wagner, D. M. (2007). Ann. N. Y. Acad. Sci. 1105, 30–66. [DOI] [PubMed]
- Laskowski, R. A. (2001). Nucleic Acids Res. 29, 221–222. [DOI] [PMC free article] [PubMed]
- Laskowski, R. A., Jabłońska, J., Pravda, L., Vařeková, R. S. & Thornton, J. M. (2018). Protein Sci. 27, 129–134. [DOI] [PMC free article] [PubMed]
- Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877.
- McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011). Acta Cryst. D67, 386–394. [DOI] [PMC free article] [PubMed]
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Radlinski, L. C., Brunton, J., Steele, S., Taft-Benz, S. & Kawula, T. H. (2018). mBio, 9, e01471-18. [DOI] [PMC free article] [PubMed]
- Rittmann, D., Schaffer, S., Wendisch, V. F. & Sahm, H. (2003). Arch. Microbiol. 180, 285–292. [DOI] [PubMed]
- Santic, M., Molmeret, M., Klose, K. E. & Abu Kwaik, Y. (2006). Trends Microbiol. 14, 37–44. [DOI] [PubMed]
- Sjöstedt, A. (2006). Microbes Infect. 8, 561–567. [DOI] [PubMed]
- Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235–242. [DOI] [PMC free article] [PubMed]
- Wolf, N. M., Gutka, H. J., Movahedzadeh, F. & Abad-Zapatero, C. (2018). Acta Cryst. D74, 321–331. [DOI] [PMC free article] [PubMed]
- Ziveri, J., Barel, M. & Charbit, A. (2017). Front. Cell. Infect. Microbiol. 7, 96. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Figures and Tables. DOI: 10.1107/S2053230X20013370/dw5213sup1.pdf